Langhe Medical
Providing robotic solutions for early diagnosis and early non-invasive interventional treatment of lung cancer
About Langhe Medical
Langhe Medical, established in 2015 by founder and CEO Dr. Jiajun Ma, is a medical technology company focused on the development of surgical robots for minimally invasive diagnosis and treatment. The company was founded in Shanghai's Lingang Global Innovation and Entrepreneurship Zone and now operates its headquarters in Shanghai, with a GMP production and R&D base in Changzhou. Langhe Medical has secured significant funding through multiple rounds, including a Series C in late 2023, backed by various venture capital and state-backed investment firms.
The company operates in the advanced medical device market, specifically targeting the diagnosis and treatment of pulmonary diseases like lung cancer. Its primary clients are top-tier hospitals in China. The business model centers on the development and sale of sophisticated medical equipment, aiming to provide high-end technology at a more accessible cost for the Chinese market. This strategy is supported by a close research and development partnership with Tsinghua University. The company has gained both EU CE and Chinese quality system certifications.
Langhe Medical's flagship product is the Unicorn™ (Kylin™), which was the first flexible endoscopic surgical robot developed in China with fully proprietary intellectual property, released in 2021. This system is designed for transbronchial procedures, offering a minimally invasive approach to diagnose and treat lung conditions. Key features include a beyond-line-of-sight navigation system that combines real-time physical positioning with optical-field fusion, AI-powered automatic planning, and 5G remote control capabilities. The product portfolio also encompasses a broader range of solutions, including visual range navigation systems and interventional teaching solutions, creating a comprehensive platform for lung disease intervention.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Open positions
- None listed
- Industry
- Health, Robotics
- Sector
- Hard Tech, DT and LS
- Technology
- Deep Tech
- Business model
- Manufacturing
- Client focus
- B2B
- Links
- Website
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES C✓Equity / VC | Dec 2023 | $14M | $55M | Shangguo Investment Management · Jiuyou Fund | ↗ |
| SERIES BEquity / VC | Apr 2022 | $0 | — | Undisclosed | ↗ |
Growth signals
Latest recorded traffic for Langhe Medical is 880 monthly website visits, up 158.8% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Langhe Medical in the Huangpu ecosystem
The Langhe Medical office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later2 investors entered at this stage
- SMShangguo Investment Management
- JFJiuyou Fund
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Langhe Medical on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Langhe Medical’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









